Neuronetics, Inc., a publicly traded company symbolized as STIM, is a prominent player in the medical technology industry. Founded in 2003, the Pennsylvania-based company's mission is anchored on transforming lives through advanced neuromodulation therapies that create lasting change for people suffering from psychiatric disorders.
The company pioneered TMS (Transcranial Magnetic Stimulation) Therapy for the treatment of Major Depressive Disorder (MDD). This innovative, non-drug and non-invasive method utilizes magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. It's a therapy option for patients who have not received satisfactory results from initial antidepressant medication.
Neuronetics' flagship product, the NeuroStar® Advanced Therapy System, is the first TMS device to receive FDA clearance in the United States (2008) for patients who have not benefited from prior antidepressant medication. This system is designed to deliver a wide range of treatment options because every patient's needs and treatment responses can be unique. It allows the practitioner to adjust the power level, pulse frequency, treatment duration, and the coil positioning to thoroughly target the treatment area.
Being at the forefront of brain health, Neuronetics always strives to innovate within neuromodulation therapies. This is driven by a solid commitment to patient needs, solid clinical evidence, and extensive safety data. The company has a seasoned leadership team with a proven track record in healthcare, combined with extensive brain health experience.
Neuronetics' approach to depressive disorder treatment has brought them recognition within the sector by leading mental health advocacy organizations. Although the NeuroStar system and its pioneering TMS therapy is their primary offering, Neuronetics intends to expand their impact within neuromodulation treating other psychiatric disorders.
Over the years, the company has steadfastly remained committed to improving the lives of patients suffering from psychiatric disorders. Neuronetics endeavors to offer effective solutions that empower clinicians to deliver the highest standards of care. It’s a mission that extends beyond product creation, as Neuronetics drives awareness of MDD and access to their novel treatments through advocacy and partnerships.
In summary, Neuronetics has been an instrumental force in revolutionizing our understanding and treatment of psychiatric disorders. The company continues reinforcing its commitment to transformative neuromodulation therapies to address unmet needs in mental health, which positions them to lead in this growing market.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
B Riley initiated coverage on Neuronetics (STIM) with a buy rating and a $5 price target, citing the company's potential to benefit from a shift towards psychedelic-driven interventional psychiatry. This target represents approximately 66% upside based on the stock's closing price on September 10th.
Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology, announced the integration of its TrakStar® practice management platform with AdvancedMD, a cloud-based electronic health record (EHR) system. This collaboration marks the first time a TMS system has integrated with an EHR/EMR, aiming to reduce administrative burden and streamline workflows for providers. The integration will be accessible to NeuroStar providers using or adopting AdvancedMD, allowing them to focus more on patient care.
Neuronetics has appointed Nir Naor as its principal financial and accounting officer, effective August 12, 2026. He was previously named executive vice president, CFO, and treasurer on July 23, 2026, and his title was updated to include corporate secretary. Francis X. Brown III stepped down from the interim role but will remain as a consultant.
Major shareholder Jorey Chernett recently purchased 14,000 shares of Neuronetics (NASDAQ:STIM) stock for $44,240.00, increasing his total ownership to over 10.6 million shares. This transaction follows a previous purchase in May. Neuronetics also reported better-than-expected quarterly earnings and revenue, while analysts currently hold a "Moderate Buy" rating for the stock with an average price target of $4.50.